Fovero Therapeutics is an Australian biotechnology company developing a new immunotherapy for treating immuno-oncology (IO) resistant cancer patients.

We have leveraged cutting-edge research in the field of dysregulated immune function, to develop a novel solution that holds the potential to transform patient care.

At the core of our scientific endeavors lies the understanding that uncontrolled infectious diseases, cancer, and autoimmune diseases share a common etiology of dysregulated immune function. This key insight forms the foundation upon which our research and development efforts are built.

Our proprietary Galectin-9 platform leverages this insight to overcome IO resistance in solid tumours. The lead antibody improves the efficiency of multiple immune cells to kill cancer cells. In preclinical models, our anti-GAL9 treatment completely controlled primary CT26 colon and 4T1.2 triple-negative breast cancer.

We are also advancing a second Galectin-9 -targeting immunotherapy designed to restore immune balance in autoimmune and inflammatory diseases.

This platform-based approach—targeting GAL9 to reprogram dysregulated immunity—is differentiated from competing therapies that act on individual checkpoint or costimulatory molecules. It offers a promising strategy to treat both cancer and immune-mediated diseases by restoring effective immune control.